Skip to content
Wenlo
Sign in
← Markets
Market closed · Opens Mon 4:00 AM ET

CADL Candel Therapeutics, Inc.

NASDAQ
$5.04−$0.09 (−1.75%)

As of 3:59 PM ET

  • CADL

Loading chart…

Open
$5.00
Previous close
$5.13
Day range
4.90 – 5.29
52-week range
4.35 – 14.00
Volume
85.7K
Avg volume (3M)
1.2M
Market cap
$417.3M
P/E (TTM)
−7.39
EPS (TTM)
−$1.53
Beta
−0.29
Dividend yield
0.00%
Next earnings
Mar 11, 2027(estimated from past report dates; not yet confirmed by the company)
Ex-dividend
—
Sector
Healthcare

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.

CADL news and filings

Loading filings…

Filings from SEC EDGAR.